Focal Segmental Glomerulosclerosis
📧 Sign up to get email alerts when something new happens for Focal Segmental Glomerulosclerosis.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-02-17FDA Approved: FILSPARI — Original Application (Travere Therapeutics, Inc.)
FDA grants original approval for FILSPARI (sparsentan) from Travere Therapeutics for the treatment of focal segmental glomerulosclerosis.